ABSTRACT
Background and study aim COVID-19 mortality, severity, and recovery are major global concerns, but they are still insufficiently understood, particularly in the Middle East. This study focused on evaluating if there was a link between COVID-19 patients’ clinical and laboratory findings at hospital admission and disease severity and mortality.
Patients and methods A total of 180 adult Egyptian COVID-19 patients were included in this study then were categorized and compared.
Results Of all, 27.8% had severe disease, and 13.9% died during their hospital stay. Diabetes (46.7%), hypertension (36.1%), and chronic obstructive pulmonary disease (COPD) (33.3%) were the most frequent associated co-morbidities. Severe patients and non-survivors were significantly older compared to their corresponding groups. Their neutrophil count, PCT, ESR, C-reactive protein (CRP), AST, ALT, LDH, D-dimer, and ferritin levels were significantly higher (P ≤ 0.05). In contrast, their absolute lymphocyte count was significantly lower (P ≤ 0.05). COPD (OR: 3.294; 95% CI: 1.199-9.053), diabetes (OR: 2.951; 95% CI:1.070- 8.137), ferritin ≥ 350 ng/mL (OR: 11.08; 95% CI: 2.796-41.551), AST ≥ 40 IU/L (OR: 3.07; 95% CI: 1.842-7.991), CT-scoring system (CT-SS) ≥ 17 (OR: 1.205; 95% CI: 1.089-1.334) and lymphocyte count < 1×103/µL (OR: 4.002; 95% CI: 1.537-10.421), were all linked to a higher risk of COVID-19 severity. While mortality was predicted by dyspnea (OR: 4.006; 95% CI: 1.045-15.359), CT-SS ≥ 17 (OR: 1.271; 95% CI: 1.091-1.482) and AST ≥ 40 IU/L (OR: 2.89; 95% CI: 1.091-7.661).
Conclusions Clinical and laboratory data of COVID-19 patients at their hospital admission may aid in identifying early risk factors for severe illness and a high mortality rate.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
None
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Ain Shams University Faculty of Medicine Research Ethics Committee (REC)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding sources: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Conflict of interest: None
- Research design, data acquisition, analysis, and interpretation
- Drafting the paper or revising it critically
- Approving the submitted version.
We also declare that no-one who qualifies for authorship has been excluded from the list of authors.
E-mail: Dr.sara_farid{at}yahoo.com, aalaashata{at}yahoo.com, drshereenatef{at}yahoo.com, shaimaa.abdalgeleel{at}nci.cu.edu.eg, Dr.mariam_karam{at}hotmail.com
Data Availability
Data will be available upon request
ABBREVIATIONS
- ACE-2
- Angiotensin-converting enzyme-2
- COPD
- Chronic obstructive pulmonary disease
- COVID-19
- Coronavirus disease 2019
- CT-SS
- CT-scoring system
- RT- PCR
- Reverse transcription-polymerase chain reaction
- SARS-CoV-2
- Severe acute respiratory syndrome corona virus 2
- WHO
- World Health Organization.
